Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & Administrative
Others
EBIAT
Ratios

Cullinan Therapeutics (CGEM) Shares Outstanding (2020 - 2023)

Cullinan Therapeutics has reported Shares Outstanding over the past 4 years, most recently at $42.8 million for Q3 2023.

  • Quarterly results put Shares Outstanding at $42.8 million for Q3 2023, down 6.52% from a year ago — trailing twelve months through Sep 2023 was $42.8 million (down 6.52% YoY), and the annual figure for FY2022 was $45.8 million, up 3.4%.
  • Shares Outstanding for Q3 2023 was $42.8 million at Cullinan Therapeutics, roughly flat from $42.7 million in the prior quarter.
  • Over the last five years, Shares Outstanding for CGEM hit a ceiling of $45.8 million in Q4 2022 and a floor of $200000.0 in Q2 2021.
  • Median Shares Outstanding over the past 4 years was $42.8 million (2023), compared with a mean of $35.2 million.
  • Biggest five-year swings in Shares Outstanding: crashed 99.0% in 2021 and later skyrocketed 22598.2% in 2022.
  • Cullinan Therapeutics' Shares Outstanding stood at $29.8 million in 2020, then skyrocketed by 48.48% to $44.3 million in 2021, then increased by 3.4% to $45.8 million in 2022, then decreased by 6.63% to $42.8 million in 2023.
  • The last three reported values for Shares Outstanding were $42.8 million (Q3 2023), $42.7 million (Q2 2023), and $39.3 million (Q1 2023) per Business Quant data.